negative regulator of antiviral responseGenealiases: DYNLL1-AS1 · DYNLL1AS1
Q-omics provides the consensus-scored NRAV profile across patient tissues and cancer cell-line models. NRAV expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NRAV is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NRAV RNA expression shows 19,365 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, KIRC, and KIRP as cancer lineages where NRAV shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRAV — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRAV survival associations across molecular data types. NRAV RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRAV RNA expression–survival associations across cancer types. High NRAV expression shows unfavorable associations in LIHC, PAAD, LGG and KICH, but favorable associations in UCEC and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NRAV RNA expression.
This table summarizes NRAV tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NRAV. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRAV shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, BLCA, LIHC and COAD. The KIRC box plot shows higher NRAV RNA expression in tumor versus normal tissue (log2 FC = +0.501, t-test p < 0.001).
This table shows molecular features associated with NRAV in patient tissues and cancer cell lines. In patient samples, NRAV shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
